The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs or characterized by excessive or inadequate FATP expression or activity. In particular, the present inventions concerns an anti-VEGF-B antibody or anti-sense oligonucleotide that inhibits VEGF-B transcription or translation for use in treating dyslipidemia in a human subject.